Sichuan Xieli Group is a large-scale Sino foreign joint venture specializing in the research, development, and production of pharmaceutical and biotechnology engineering. It currently has multiple production bases, including Sichuan Xieli Pharmaceutical Co., Ltd., Chengdu Jianjiang Pharmaceutical Factory, Chengdu Xieli Zhongkangzhi Development Co., Ltd., Sichuan Xieli Medical Technology Co., Ltd., and Sichuan Xieli Traditional Chinese Medicine Planting Base. The group covers an area of 200000 square meters and currently employs 400 people. It has advanced and complete process equipment and first-class technical talents, and has established good technical support relationships with multiple national scientific research institutions, with considerable technical strength. The marketing network of the Group covers the whole country, and its performance in the pharmaceutical and health care products market in the whole country and Southeast Asia is remarkable. The Group has a huge marketing team of nearly 1000 people, covering multiple traditional Marketing channel such as clinical promotion, general drug distribution, OTC, health care products, raw material supply, trade export, and so on. Its annual export volume is nearly 10 million dollars, and its marketing strength has always been in the leading position in China's pharmaceutical market. Sichuan Xieli Group mainly produces over 100 product series, including raw materials, pharmaceutical intermediates, functional health foods, tablets, capsules, granules, and disinfection and hygiene products. The main API products include more than 10 varieties, including rutin, troxerutin J, soybean Isoflavone, Camptothecin, paclitaxel and Quercetin. The newly developed "troxerutin API" was rated as "national key new product". In 2003, the company invested 60 million yuan in technological transformation to improve the overall scientific research level and new product development capacity of the group. At present, the product quality has reached and exceeded the current pharmacopoeia standards of the United States, Britain, France, Germany, Japan and Europe, and has successfully passed the GMP certification of the State Food and Drug Administration. In terms of extracting raw materials from plant drugs, Xieli has become one of the largest production bases.